Peplens

Thymosin Alpha-1

Limited human data

Synthetic 28-amino-acid thymic peptide / immune modulator (Toll-like-receptor and T-cell modulator) · Also known as Thymalfasin, Zadaxin, TA1, Talpha1

Overview

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue that modulates the immune system — promoting maturation and function of T-cells, influencing dendritic cells and Toll-like-receptor signaling, and broadly acting as an immune 'tuner' rather than a simple stimulant. It is among the better-studied compounds here, with substantial international clinical use: marketed as Zadaxin (thymalfasin), it is approved in 35-plus countries (including China and Italy) primarily for chronic hepatitis B and as an immune-enhancing adjunct, and it has been studied in sepsis, cancer immunotherapy and respiratory infection. The crucial US nuance: despite decades of use abroad, thymosin alpha-1 is NOT FDA-approved in the United States — the manufacturer reportedly judged US registration trials too costly given the market — so in the US it is not an approved drug. Human evidence for many of its popularly marketed 'immune optimization' and longevity uses remains incomplete.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

  • Chronic hepatitis B (approved abroad as Zadaxin; NOT FDA-approved in the US)
  • Immune support / immunosenescence and infection resilience (marketed claim; mixed and incomplete human evidence for general use)
  • Adjunct in sepsis and cancer immunotherapy (studied internationally; results mixed, not a US-approved use)
  • General 'immune optimization' and longevity (marketed claim; not established)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

  • Labs — white-cell count and lymphocyte subsets (e.g., CD4/CD8) if a clinician is monitoring immune status
  • Labs — hs-CRP and IL-6 for an inflammation/recovery goal; liver enzymes (ALT/AST) and viral markers if used for a hepatitis indication under a clinician abroad
  • Subjective — frequency/severity of infections and general energy over time
  • WHOOP — recovery, HRV and sleep trends as a well-being signal
  • Subjective — daily energy and recovery check-ins

Sources & References

  1. [1]Thymosin alpha 1: a comprehensive review of the literature — PMC
  2. [2]Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection (NCT04487444) — ClinicalTrials.gov
  3. [3]Thymalfasin — PubChem

Quick Reference

Class
Synthetic 28-amino-acid thymic peptide / immune modulator (Toll-like-receptor and T-cell modulator)
Evidence Level
Limited human data
Reported Uses
4 listed
Tracking Metrics
5 suggested
Citations
3 sources

Safety & legal notes

NOT FDA-approved in the United States — this is the key point. It IS approved as Zadaxin (thymalfasin) in 35-plus countries for chronic hepatitis B and immune indications, so 'approved' status is geographic and does not extend to the US. In the US it is accessed off-label through compounding pharmacies; following the February 2026 reclassification it was placed in FDA 503A Category 2, but Category status is not the same as FDA approval. Generally well tolerated in studies, but long-term outcome data for popular off-label uses is limited. Athletes should verify current WADA/sport rules before use. Consult a licensed clinician.

Track your protocol in Peplens

Connect your InBody, Whoop, smart scale, and nutrition data. See your Overlay — all metrics, one clear read.

Get started free →
← All entries